Rafael Holdings Says European Medicines Agency Grants Orphan Drug Designation To Co’s CPI-613 For Treatment Of Patients With Relapsed Or Refractory Burkitt’s Lymphoma

by Yogesh Tanwar | Nov 3, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.